IsoBlog

Isotopia's Home page » IsoBlog

Marking International Parkinson’s Disease Day: The Power of [18F]-FDOPA PET/CT in Diagnosis

10/04/2025

THE CLINICAL UTILITY OF PSMA-11

05/01/2025

The Role of Aseptic Manufacturing in Ensuring Drug Safety

02/01/2025

PSMA-11: The Gold Standard in Prostate Cancer Imaging

05/11/2024

Unveiling the Significance of SUV Measure in Theranostics

09/05/2024

Nuclear Medicine role in Neuroendocrine Tumors

17/01/2024

Terbium 161 for Targeted Radionuclide Therapy in Oncology

15/10/2023

Terbium-161 Radionuclide Therapy in Prostate Cancer

15/10/2023

Radiopharmacy and Radiobiology Aspects for 161-Terbium

10/10/2023

The Future of Theranostics in Prostate Cancer- PSMA RLT and Combination Therapy

21/08/2023

Is there a future for PSMA theranostics in Osteosarcoma?

16/03/2023

PSMA theranostics in tumors other than prostate cancer

25/12/2022

Nuclear imaging in Parkinson’s disease- The past, the present, and the future

16/05/2022

Overcoming Lutetium-177 Production and Supply Challenges

21/04/2022

Vision study – Research on Prostate Cancer

16/04/2020

proPSMA studies - Isotopia

proPSMA study

06/04/2020

18f dopa use in parkinsonism - Isotopia

18F-DOPA use in Parkinsonism

16/02/2020

Lutetium 177 production as GMP grade - Isotopia

Lutetium 177 production (Lu177 production)

10/02/2020

NUCLEAR MOLECULAR CANCER THERAPY - Isotopia

PERSONALIZED NUCLEAR MOLECULAR CANCER THERAPY

03/02/2020

metastatic prostate cancer treatment - Isotopia

Prostate cancer

03/02/2020